Literature DB >> 29256127

5α-Reductase Inhibitors (5ARIs) and Male Reproduction.

Erma Z Drobnis1, Ajay K Nangia2.   

Abstract

The 5ARIs, finasteride and dutasteride, are used to treat benign prostate hyperplasia and lower urinary tract symptoms. At much lower doses, 5ARI treatment reduces male hair loss. These drugs inhibit the conversion of testosterone to the more active dihydrotestosterone (DHT). In men taking these medications, DHT levels are reduced by some 90% while testosterone levels remain relatively stable. Well known for their negative effects on libido and erectile function, 5ARIs also cause ejaculatory dysfunction in some men, having the potential to decrease semen quality. In fact, some studies of men treated with these drugs have reported lower total sperm count, along with lower sperm motility, although the changes are probably insufficient to reduce fertility in men with normal semen before treatment. There is a population of men with more severely decreased sperm numbers; as low as 10% of pretreatment values. Fewer studies have looked at the lower doses used for male alopecia, indicating little affect in men with normal semen quality, but a negative effect on sperm numbers in men with oligozoospermia. There have been no studies looking at fertility endpoints for these medications.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29256127     DOI: 10.1007/978-3-319-69535-8_7

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  7 in total

Review 1.  The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men's Health.

Authors:  Mohammed A Said; Akanksha Mehta
Journal:  Curr Urol Rep       Date:  2018-06-16       Impact factor: 3.092

2.  Improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasteride.

Authors:  Kirill V Kosilov; Irina G Kuzina; Vladimir Kuznetsov; Ekaterina K Kosilova
Journal:  Prostate Int       Date:  2020-02-25

3.  Evaluation of the impact of dutasteride/tamsulosin combination therapy on libido in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH): A post hoc analysis of a prospective randomised placebo-controlled study.

Authors:  Raymond C Rosen; Claus G Roehrborn; Michael J Manyak; Juan Manuel Palacios-Moreno; Timothy H Wilson; Zrinka Lulic; Francois Giuliano
Journal:  Int J Clin Pract       Date:  2018-11-05       Impact factor: 2.503

Review 4.  Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia.

Authors:  Zhao-Jun Yu; Hai-Lan Yan; Fang-Hua Xu; Hai-Chao Chao; Lei-Hong Deng; Xiang-Da Xu; Jian-Biao Huang; Tao Zeng
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

5.  Efficacy of a combination of dutasteride, tadalafil, and solifenacin in the treatment of previously unsuccessful patients.

Authors:  Kirill Kosilov; Irina Kuzina; Vladimir Kuznetsov; Olga Barabash; Ekaterina Fedorishcheva
Journal:  Asian J Urol       Date:  2021-04-20

6.  Anti-acne vulgaris effect including skin barrier improvement and 5α-reductase inhibition by tellimagrandin I from Carpinus tschonoskii.

Authors:  Jun Yin; In Hyoek Hwang; Min Won Lee
Journal:  BMC Complement Altern Med       Date:  2019-11-21       Impact factor: 3.659

7.  Serum concentrations of dihydrotestosterone are associated with symptoms of hypogonadism in biochemically eugonadal men.

Authors:  A Sansone; S Kliesch; M Dugas; R Sandhowe-Klaverkamp; A M Isidori; S Schlatt; M Zitzmann
Journal:  J Endocrinol Invest       Date:  2021-04-03       Impact factor: 4.256

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.